FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022649404> ?p ?o ?g. }

• W2022649404 endingPage "2020" @default.
• W2022649404 startingPage "2013" @default.
• W2022649404 abstract "Background. Genetically engineered tumor vaccines are feasible for clinical trials in human prostate cancer, and Phase I testing has been approved. The Dunning rat prostate cancer model provides an opportunity for translational research to rationally design Phase II clinical studies testing efficacy. Methods. The Dunning R3327 MAT-LyLu subline was transduced with the retroviral vector MFG carrying the cytokine gene for human granulocyte-macrophage colony-stimulating factor (GM-CSF). Varying secretion rates of human GM-CSF were generated and tumor cell vaccines were formulated, consisting of 5 X 10 6 lethally irradiated transduced cells. The vaccines were placed at a subcutaneous site opposite preestablished tumor of 1 X 10 4 cells implanted 3 days earlier in Copenhagen rats. Trials were masked, randomized, and conducted over 6-week intervals using different treatment schedules, vaccine number, and varying doses of human GM-CSF secretion as well as appropriate controls. Results. Thirty percent of rats with long term follow-up can be cured of preestablished tumor burdens with human GM-CSF transduced tumor vaccines secreting greater than 140 ng/10 6 cells/24 hours of human GM-CSF. All studies evaluating more than one vaccine over a wide range of human GM-CSF secretion rates show significant delays in tumor appearance and progression. One vaccination is not curative. Vaccination with GM-CSF transduced tumor vaccines increased disease free survival and slowed tumor progression over animals vaccinated with irradiated tumor cells admixed with either soluble GM-CSF or with a nonspecific immune adjuvant (Corynebacterium parvum). The ability to cure animals and delay progression appears related to total duration of human GM-CSF secretion at the subcutaneous site. Systemic human GM-CSF could be detected in the serum of rats for at least 6 days after vaccination. Conclusions. These data have implications for the design of gene therapy trials in prostate cancer. Small androgen independent tumor burdens such as volumes seen in the adjuvant setting can be cured. Multiple vaccinations with adequate human GM-CSF secretion are required. At higher human GM-CSF secretion rates, systemic levels may be achievable, and patients should be evaluated closely for toxicity to and the pharmacokinetics of GM-CSF. Concer 1995 ; 75 :2013-20." @default.
• W2022649404 created "2016-06-24" @default.
• W2022649404 creator A5001783218 @default.
• W2022649404 creator A5004417664 @default.
• W2022649404 creator A5009605331 @default.
• W2022649404 creator A5085423716 @default.
• W2022649404 date "1995-04-01" @default.
• W2022649404 modified "2023-09-26" @default.
• W2022649404 title "Gene therapy for human prostate cancer. Translational research in the hormone refractory dunning prostate cancer model" @default.
• W2022649404 cites W1978416272 @default.
• W2022649404 cites W1989775015 @default.
• W2022649404 cites W1990668606 @default.
• W2022649404 cites W1991148746 @default.
• W2022649404 cites W2032072397 @default.
• W2022649404 cites W2045724858 @default.
• W2022649404 cites W2050842983 @default.
• W2022649404 cites W2051364753 @default.
• W2022649404 cites W2053670125 @default.
• W2022649404 cites W2057218203 @default.
• W2022649404 cites W2076479500 @default.
• W2022649404 cites W2087360336 @default.
• W2022649404 cites W2091691801 @default.
• W2022649404 cites W2091987058 @default.
• W2022649404 cites W2160015737 @default.
• W2022649404 cites W2270947610 @default.
• W2022649404 cites W2404892170 @default.
• W2022649404 cites W2423112668 @default.
• W2022649404 cites W2593892363 @default.
• W2022649404 cites W3005498893 @default.
• W2022649404 doi "https://doi.org/10.1002/1097-0142(19950401)75:7+<2013::aid-cncr2820751643>3.0.co;2-p" @default.
• W2022649404 hasPublicationYear "1995" @default.
• W2022649404 type Work @default.
• W2022649404 sameAs 2022649404 @default.
• W2022649404 citedByCount "12" @default.
• W2022649404 countsByYear W20226494042012 @default.
• W2022649404 crossrefType "journal-article" @default.
• W2022649404 hasAuthorship W2022649404A5001783218 @default.
• W2022649404 hasAuthorship W2022649404A5004417664 @default.
• W2022649404 hasAuthorship W2022649404A5009605331 @default.
• W2022649404 hasAuthorship W2022649404A5085423716 @default.
• W2022649404 hasConcept C104317684 @default.
• W2022649404 hasConcept C111599444 @default.
• W2022649404 hasConcept C121608353 @default.
• W2022649404 hasConcept C126322002 @default.
• W2022649404 hasConcept C128544194 @default.
• W2022649404 hasConcept C142424586 @default.
• W2022649404 hasConcept C142724271 @default.
• W2022649404 hasConcept C143998085 @default.
• W2022649404 hasConcept C2776235491 @default.
• W2022649404 hasConcept C2780192828 @default.
• W2022649404 hasConcept C2780275930 @default.
• W2022649404 hasConcept C29456083 @default.
• W2022649404 hasConcept C502942594 @default.
• W2022649404 hasConcept C530470458 @default.
• W2022649404 hasConcept C54355233 @default.
• W2022649404 hasConcept C71924100 @default.
• W2022649404 hasConcept C86803240 @default.
• W2022649404 hasConcept C87355193 @default.
• W2022649404 hasConceptScore W2022649404C104317684 @default.
• W2022649404 hasConceptScore W2022649404C111599444 @default.
• W2022649404 hasConceptScore W2022649404C121608353 @default.
• W2022649404 hasConceptScore W2022649404C126322002 @default.
• W2022649404 hasConceptScore W2022649404C128544194 @default.
• W2022649404 hasConceptScore W2022649404C142424586 @default.
• W2022649404 hasConceptScore W2022649404C142724271 @default.
• W2022649404 hasConceptScore W2022649404C143998085 @default.
• W2022649404 hasConceptScore W2022649404C2776235491 @default.
• W2022649404 hasConceptScore W2022649404C2780192828 @default.
• W2022649404 hasConceptScore W2022649404C2780275930 @default.
• W2022649404 hasConceptScore W2022649404C29456083 @default.
• W2022649404 hasConceptScore W2022649404C502942594 @default.
• W2022649404 hasConceptScore W2022649404C530470458 @default.
• W2022649404 hasConceptScore W2022649404C54355233 @default.
• W2022649404 hasConceptScore W2022649404C71924100 @default.
• W2022649404 hasConceptScore W2022649404C86803240 @default.
• W2022649404 hasConceptScore W2022649404C87355193 @default.
• W2022649404 hasIssue "S7" @default.
• W2022649404 hasLocation W20226494041 @default.
• W2022649404 hasOpenAccess W2022649404 @default.
• W2022649404 hasPrimaryLocation W20226494041 @default.
• W2022649404 hasRelatedWork W1980245127 @default.
• W2022649404 hasRelatedWork W2001670844 @default.
• W2022649404 hasRelatedWork W2012224485 @default.
• W2022649404 hasRelatedWork W2069528600 @default.
• W2022649404 hasRelatedWork W2106003470 @default.
• W2022649404 hasRelatedWork W2146454333 @default.
• W2022649404 hasRelatedWork W2400504790 @default.
• W2022649404 hasRelatedWork W2429027331 @default.
• W2022649404 hasRelatedWork W2433835599 @default.
• W2022649404 hasRelatedWork W4238595775 @default.
• W2022649404 hasVolume "75" @default.
• W2022649404 isParatext "false" @default.
• W2022649404 isRetracted "false" @default.
• W2022649404 magId "2022649404" @default.
• W2022649404 workType "article" @default.